Pulmonary Central, Author at PulmCCM
Advertisement

Pulmonary Central

Pulmonary Central was the previous name for the PulmCCM blog. The PulmCCM team writes the posts under this moniker. Read the About page for more of the PulmCCM Central story.

Jan 252015
 

Hot off the blog-press is PulmCCM’s new Educational Resources section. This exciting new endeavor will be a forum for sharing your knowledge with the world. If you’ve created a useful educational clinical resource, why limit your audience to your colleagues at your local institution? Increase your impact exponentially by posting your work on PulmCCM where thousands can learn and benefit. [… read more]

Jan 192015
 
Should video-guided intubation be standard training in critical care? (And should anesthesiologists teach it?)

Image: Airwaycam Endotracheal intubation is a routine but high-stakes maneuver, performed uneventfully thousands of times daily throughout the developed world. In the U.S., elective (routine) intubation is almost exclusively the domain of anesthesiologists, who become masters of the technique through thousands of iterations throughout training and their careers. The vast majority of these intubations take [… read more]

Jan 192015
 
Subglottic suctioning prevents ventilator-associated pneumonia

Subglottic suctioning can prevent ventilator-associated pneumonia (VAP), but much of the research showing its benefits was performed prior to wide adoption of the so-called “VAP bundle,” widely believed to reduce VAP incidence. This led some to question any additive benefits of subglottic suctioning. Authors of a new randomized trial found that subglottic suctioning also reduced ventilator-associated pneumonia incidence in a [… read more]

Jan 112015
 
Nutrition in severe pancreatitis: none at all (for 3 days) worked fine

Image: Wikipedia Acute pancreatitis is a common and usually self-limited illness resolving after a few days of rest and not eating. A minority of people develop severe pancreatitis with necrosis, which can transform pancreatitis into an ordeal lasting weeks or months, characterized by multi-organ failure, infections, and a >15% mortality rate. Those infections are believed to be caused by [… read more]

Jan 102015
 
Cytisine for smoking cessation: as good as nicotine replacement -- and cheap

The smoking cessation drug varenicline (Chantix) works by weakly activating and also blocking nicotine receptors in the brain, simultaneously. This neat trick has the dual effects of reducing tobacco cravings while also blunting the “high” from smoking. That combination has made Chantix the most successful smoking-cessation therapy on the market, but it costs about $500 for [… read more]

Jan 052015
 

Here are some of the biggest stories and most important published research findings in critical care and respiratory medicine for 2014. Enjoy, and subscribe to the PulmCCM weekly email newsletter to stay up to date in pulmonary and critical care. Early goal directed therapy does not improve outcomes in septic shock (ProCESS) Are traditional protocols [… read more]

Dec 212014
 
Ischemic stroke: Interventional treatment + alteplase = new standard of care? (MR CLEAN)

In the early 1990s, the clot-busting drug alteplase (intravenous recombinant tissue plasminogen activator or rTPA) revolutionized stroke treatment when it was shown to significantly increase the chances of a good outcome after ischemic stroke when given in the first 4.5 hours since symptom onset. But alteplase is not a miracle drug. In a meta-analysis of 9 randomized trials, rTPA improved [… read more]

Dec 192014
 
Age-adjusted D-dimer to rule out PE: coming of age?

Put a CT scanner in every U.S. emergency department, add the non-specific signs and symptoms of pulmonary embolism, stir in its potential lethality and morbidity, and line up a few thousand lawyers on the sidelines ready to capitalize on any missed diagnoses, and it’s no wonder that the use of CT-angiograms to rule out pulmonary embolism has risen 11-fold [… read more]

Dec 072014
 

Ignoring its advisory panel, the Centers for Medicare and Medicaid Services (CMS) announced that annual low-dose CT lung cancer screening for high-risk individuals will be covered by Medicare. However, CMS applied restrictions that will limit access to screening, avoiding the chaotic marketplace free-for-all that would have resulted from an unrestricted approval. Medicare will pay for one lung cancer [… read more]

Oct 312014
 
Life after sepsis protocols: What now? (You decide.)

2014 has been a rough year for advocates of sepsis protocols. First, the long-awaited ProCESS trial did not show any benefit from use of the original early goal-directed therapy (EGDT) protocol used in the single-center 2001 trial by Rivers et al that, despite criticism, became the standard of care for the following decade. Patients cared for in the 2 non-EGDT arms [… read more]

Oct 312014
 
Safe to stop inhaled steroids in COPD (and start more expensive drugs)?

Olodaterol People with severe chronic obstructive pulmonary disease (COPD) often have persistent dyspnea or exacerbations despite the use of a single controller inhaler. (Controller inhalers for COPD most often include combination inhaled corticosteroid/long-acting beta agonists like Advair, Dulera and Symbicort [ICS/LABAs] and the long-acting anticholinergic agent Spiriva/tiotropium). These patients often take both a combination ICS/LABA and Spiriva, so-called [… read more]

Oct 172014
 
FDA approves pirfenidone (Esbriet) and nintedanib (Ofev) for IPF

The U.S. FDA approved the first two drugs proven to slow progression of idiopathic pulmonary fibrosis (IPF): pirfenidone (Esbriet by Roche, which bought Intermune) and nintedanib (Ofev by Boehringer Ingelheim) on Wednesday October 15. Both drugs will offer new hope for patients, and new pain to the insurance companies and the government who pay for them. Pirfenidone [… read more]

Oct 142014
 
Total parenteral nutrition vs enteral nutrition: no difference in critically ill? (CALORIES trial)

Feeding patients enterally (nasogastric or nasojejunal tube feedings) has been the standard of care for critically ill patients, based on weak evidence that it reduces infection rates; hence the adage “feed the gut, if you can.” That last caveat is included because so many critically ill patients have gastric motility impairment (with inability to achieve [… read more]

Oct 102014
 
Transfusion for hemoglobin above 7 g/dL: no benefit in septic shock (TRISS Trial)

Blood transfusions have been a central component of protocols for care of severe sepsis and septic shock, ever since the single-center 2001 Rivers trial included them in its interventions. Any benefit (or harm) caused by red cell transfusion independently was unknowable, and so the therapy became standard care as part of the so-called sepsis bundle. The Surviving [… read more]

Oct 052014
 
Are traditional protocols for goal directed therapy for sepsis dead? (ARISE trial)

Update: As astute commenters have mentioned below, and as I stated in our post on the ProCESS trial, protocols of some kind could still have a place in the care of sepsis if they ensure more rapid recognition and thorough treatment. Accordingly, I changed the headline to clarify that it’s only traditional sepsis protocols to which I refer, not the [… read more]

Sep 122014
 

All the best in the pulmonary and critical care medicine literature from our ongoing journal survey. Browse all the PulmCCM Roundups to stay up to date. Thrombolytics for Pulmonary Embolism: New Metaanalysis Most patients with massive pulmonary embolism (PE with shock) should receive thrombolytics, but it’s unclear from randomized trial data which patients with submassive pulmonary embolism [… read more]

Sep 052014
 
New 2014 Pulmonary Hypertension guidelines released

The American College of Chest Physicians (unaffiliated with PulmCCM) published its new consensus guidelines in August 2014 for the drug treatment of pulmonary arterial hypertension (PAH). They’re free to view on the Chest website, and well worth a look. Remember that pulmonary arterial hypertension (PAH) is but one small subset (“Group 1″) of the much larger [… read more]

Aug 162014
 
Which cancer patients need prophylaxis for DVT and pulmonary embolism?

People with cancer have the highest rates of deep venous thrombosis (DVT) and pulmonary embolism (PE). However, the risk of venous thromboembolism varies widely by cancer type and between patients. Daily anticoagulant use can reduce the risk of DVT and pulmonary embolism, but at a cost of increased bleeding risk, patient inconvenience and discomfort, and cost. [… read more]

Jul 302014
 
What are Ventilator-Associated Events (and why should you care)?

Have you heard of ventilator-associated events (VAEs)? Like it or not, this neologism of healthcare-speak is coming to an ICU near you soon. Here’s the lowdown on VAEs and why they matter to the practicing intensivist. What are Ventilator-Associated Events? Ventilator-associated events are an invention of the Centers for Disease Control and Prevention (CDC), created in [… read more]